TY - JOUR
T1 - Targeting the multifaceted neurotoxicity of Alzheimer's disease by tailored functionalisation of the curcumin scaffold
AU - De Lorenzi, Ersilia
AU - Seghetti, Francesca
AU - Tarozzi, Andrea
AU - Pruccoli, Letizia
AU - Contardi, Cecilia
AU - Serra, Massimo
AU - Bisi, Alessandra
AU - Gobbi, Silvia
AU - Vistoli, Giulio
AU - Gervasoni, Silvia
AU - Argentini, Carla
AU - Ghirardo, Giulia
AU - Guarato, Giulia
AU - Orso, Genny
AU - Belluti, Federica
AU - Di Martino, Rita Maria Concetta
AU - Zusso, Morena
N1 - Publisher Copyright:
© 2023 Elsevier Masson SAS
PY - 2023/4/5
Y1 - 2023/4/5
N2 - Simultaneous modulation of multifaceted toxicity arising from neuroinflammation, oxidative stress, and mitochondrial dysfunction represents a valuable therapeutic strategy to tackle Alzheimer's disease. Among the significant hallmarks of the disorder, Aβ protein and its aggregation products are well-recognised triggers of the neurotoxic cascade. In this study, by tailored modification of the curcumin-based lead compound 1, we aimed at developing a small library of hybrid compounds targeting Aβ protein oligomerisation and the consequent neurotoxic events. Interestingly, from in vitro studies, analogues 3 and 4, bearing a substituted triazole moiety, emerged as multifunctional agents able to counteract Aβ aggregation, neuroinflammation and oxidative stress. In vivo proof-of-concept evaluations, performed in a Drosophila oxidative stress model, allowed us to identify compound 4 as a promising lead candidate.
AB - Simultaneous modulation of multifaceted toxicity arising from neuroinflammation, oxidative stress, and mitochondrial dysfunction represents a valuable therapeutic strategy to tackle Alzheimer's disease. Among the significant hallmarks of the disorder, Aβ protein and its aggregation products are well-recognised triggers of the neurotoxic cascade. In this study, by tailored modification of the curcumin-based lead compound 1, we aimed at developing a small library of hybrid compounds targeting Aβ protein oligomerisation and the consequent neurotoxic events. Interestingly, from in vitro studies, analogues 3 and 4, bearing a substituted triazole moiety, emerged as multifunctional agents able to counteract Aβ aggregation, neuroinflammation and oxidative stress. In vivo proof-of-concept evaluations, performed in a Drosophila oxidative stress model, allowed us to identify compound 4 as a promising lead candidate.
KW - Alzheimer's disease
KW - Amyloid beta oligomers
KW - Curcumin analogues
KW - Drosophila Melanogaster model
KW - Natural products
KW - Neuroinflammation
KW - Oxidative stress
UR - https://www.scopus.com/pages/publications/85151422536
U2 - 10.1016/j.ejmech.2023.115297
DO - 10.1016/j.ejmech.2023.115297
M3 - Article
SN - 0223-5234
VL - 252
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 115297
ER -